Veracyte Is Maintained at Buy by Needham
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Raises Target Price to $37
Morgan Stanley Maintains Veracyte(VCYT.US) With Sell Rating, Maintains Target Price $26
Veracyte Analyst Ratings
Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $26
Analyst Issues Sell Rating for Veracyte Amidst Strong Q2 Growth but Limited Near-Term Upside
Veracyte (VCYT) Receives a Buy From Scotiabank
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), ADMA Biologics (ADMA) and Veracyte (VCYT)
Veracyte's Growth Momentum and Robust Test Adoption Fuel Buy Rating
Veracyte Analyst Ratings
Needham Maintains Buy on Veracyte, Raises Price Target to $31
Veracyte's Strong Q1 Performance and Upbeat Outlook Justify Buy Rating
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT) and Argenx Se (ARGX)
Veracyte Analyst Ratings
Needham Maintains Buy on Veracyte, Lowers Price Target to $27
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT), Veracyte (VCYT) and Nevro Corp (NVRO)
Veracyte Analyst Ratings
Analysts' Top Healthcare Picks: BioCryst (BCRX), Veracyte (VCYT)
Veracyte Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Veracyte (VCYT), Irhythm Technologies (IRTC)